Special Issue "Resistance to Apoptosis-Based Cancer TherapyInduction of Non-apoptotic Cell Death to Overcome Chemoresistance"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 28 February 2022.

Special Issue Editors

Dr. Dayanidhi Raman
E-Mail Website
Guest Editor
1. Department of Cancer Biology, College of Medicine and Life Sciences, Health Science Campus, University of Toledo, Toledo, OH 43614, USA
2. Department of Pharmacology, Vanderbilt University, Nashville, TN, USA
Interests: chemokine receptors; chemotaxis; LASP1; cap-dependent protein translation in cancer; metastasis; breast cancer; pancreatic cancer; targeted therapy; small molecule inhibitors
Special Issues and Collections in MDPI journals
Dr. Venkataswarup Tiriveedhi
E-Mail Website
Guest Editor
1. Department of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA
2. Department of Pharmacology, Vanderbilt University, Nashville, TN, USA
Interests: breast cancer; medicine; Healthcare; immunology; cancer; transplant; role of cytokines in the development of inflammatory injury mediated carcinogenesis
Special Issues and Collections in MDPI journals
Dr. Anil Shanker
E-Mail Website
Guest Editor
Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College School of Medicine, Nashville, TN, USA
Interests: CD8 T cells (CTL); natural killer cells (NK); lymphocyte crosstalk; immune networks; cytolytic function; effector cooperativity; cancer; solid tumors; immunotherapy; neuroimmunity
Special Issues and Collections in MDPI journals
Dr. Amit K. Tiwari
E-Mail Website
Guest Editor
Frederic and Mary Wolfe Center, Department of Pharmacology Experimental Therapeutics, College of Pharmacy & Pharmaceutical Sciences, Health Science Campus, The University of Toledo, OH 43614, USA
Interests: drug resistance; chemotherapy failure; drug–drug interaction; anticancer drug discovery; novel mechanisms

Special Issue Information

Dear Colleagues,

Apoptosis is a form of regulated cell death (RCD) that is essential for organogenesis and tissue homeostasis. Apoptotic stimuli can trigger intrinsic and/or extrinsic cell death pathways. In cancer patients, apoptotic induction by neoadjuvant chemotherapy, biological therapies, and/or radiotherapy can result in cancer cell death. However, cancer cells can swiftly adapt and become refractory to apoptotic therapies, resulting in clinical resistance to apoptosis. Drug resistance or minimal residual disease contributes to the development of aggressive primary tumors and increases the propensity for metastasis to sentinel lymph nodes, visceral organs, and bones. The ensuing therapy failure decreases the overall survival and the quality of life for the patients with metastatic tumors. In order to overcome this resistance to apoptosis for neoadjuvant chemotherapy or any targeted therapy, alternative forms of RCD have been proposed for induction in apoptosis-resistant cancer cells. These include necroptosis, autophagy, ferroptosis, pyroptosis, and methuosis, some of which could be relevant as immunogenic cell death. These alternative forms of RCD can be induced singly or in combination, and may help balance the immune checkpoint inhibition and/or overall immune response. By employing transformative and transdisciplinary approaches to induce non-apoptotic forms of tumor cell death, we may pave the way for the development of novel anticancer therapies with the hope of improving patient longevity. For this Special Issue, we welcome the submission of original research articles, reviews, mini reviews, case reports, clinical trials, methods, and perspectives that deal with biomarkers/pharmacological/biological/genetic or epigenetic interventions within the broad scope of induction of non-apoptotic cell death to overcome chemoresistance.

Dr. Dayanidhi Raman
Dr. Venkataswarup Tiriveedhi
Dr. Anil Shanker
Dr. Amit K. Tiwari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • apoptosis
  • non-apoptotic cell death
  • chemoresistance
  • tumor cell death
  • regulated cell death (RCD)

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells
Cancers 2021, 13(8), 1954; https://doi.org/10.3390/cancers13081954 - 18 Apr 2021
Viewed by 478
Abstract
Enhancing the tumor immunogenic microenvironment has been suggested to circumvent triple-negative breast cancer (TNBC) resistance and increase the efficacy of conventional chemotherapy. Here, we report a novel chemotherapeutic compound, TPH104, which induces immunogenic cell death in the TNBC cell line MDA-MB-231, by increasing [...] Read more.
Enhancing the tumor immunogenic microenvironment has been suggested to circumvent triple-negative breast cancer (TNBC) resistance and increase the efficacy of conventional chemotherapy. Here, we report a novel chemotherapeutic compound, TPH104, which induces immunogenic cell death in the TNBC cell line MDA-MB-231, by increasing the stimulatory capacity of dendritic cells (DCs), with an IC50 value of 140 nM. TPH104 (5 µM) significantly increased ATP levels in the supernatant and mobilized intracellular calreticulin to the plasma membrane in MDA-MB-231 cells, compared to cells incubated with the vehicle. Incubating MDA-MB-231 cells for 12 h with TPH104 (1–5 µM) significantly increased TNF-α mRNA levels. The supernatants of dying MDAMB-231 cells incubated with TPH104 increased mouse bone marrow-derived DC maturation, the expression of MHC-II and CD86 and the mRNA expression of TNF-α, IL-6 and IL-12. Overall, these results indicate that TPH104 induces immunogenic cell death in TNBC cells, in part, by activating DCs. Full article
Show Figures

Figure 1

Back to TopTop